Summary
Amgen Inc. (AMGN) has filed an 8-K report detailing a significant debt offering completed on February 17, 2026. The company successfully issued and sold a total of $4.0 billion in senior notes across four tranches with varying maturity dates and interest rates. This offering includes $1 billion of 4.200% Senior Notes due 2031, $1.75 billion of 4.850% Senior Notes due 2036, $500 million of 5.500% Senior Notes due 2046, and $750 million of 5.650% Senior Notes due 2056. The net proceeds from this offering are approximately $3.96 billion, which will be used by the company for its general corporate purposes. The issuance of these notes, registered under an effective Form S-3, represents a strategic move to secure long-term funding. Investors should note that these senior notes rank equally with other existing and future senior unsecured indebtedness of Amgen. The terms include a provision for a change in control triggering event, where noteholders can require Amgen to repurchase their notes at 101% of the principal amount plus accrued interest. This debt financing is a material event for Amgen, impacting its capital structure and future financial obligations.
Key Highlights
- 1Amgen Inc. raised approximately $3.96 billion in net proceeds from the issuance of new senior notes.
- 2The debt offering consists of four tranches: $1 billion (4.200% due 2031), $1.75 billion (4.850% due 2036), $500 million (5.500% due 2046), and $750 million (5.650% due 2056).
- 3The notes are senior unsecured debt and rank equally with Amgen's other senior unsecured obligations.
- 4A change in control provision allows noteholders to demand repurchase at 101% of principal plus accrued interest.
- 5The offering was completed under an effective Form S-3 registration statement.
- 6The proceeds are intended for general corporate purposes.